GlassScriptPhysician profile
Marvin C Schlecte
NPI 1679791982
$2,323.68
in general payments reported to CMS, 2019-2025
13 companies · $247 in 2025
The $247 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.33 · 2021: $108 · 2022: $80.70 · 2023: $1,560 · 2024: $289 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,129 · Food and Beverage: $968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,128.94 |
| Food and Beverage | $967.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $1,372.99 | 2023 | Visumax, Artevo 800, Cirrus Hd-Oct |
| Abbvie INC. | $405.80 | 2022-2025 | Lumigan, Alphagan P |
| Alcon Vision LLC | $246.85 | 2019-2025 | Ora System Verifeye, Clareon, Eysuvis |
| Dompe US, INC. | $88.50 | 2025 | Oxervate |
| Allergan, INC. | $48.24 | 2021 | |
| Biotissue Holdings INC. | $24.04 | 2021 | |
| Amgen INC. | $23.10 | 2024 | Tepezza |
| Novartis Pharmaceuticals Corporation | $22.32 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $21.31 | 2024 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $20.11 | 2025 | |
| Oyster Point Pharma, INC. | $19.48 | 2025 | Ryzumvi, Tyrvaya |
| Bausch & Lomb Americas INC. | $17.78 | 2024 | Xiidra, Miebo |
| Aerie Pharmaceuticals, INC. | $13.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Schlecte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.